Amiorone

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Amiorone

Quick Facts

Property Description
Active ingredient Amiodarone Hydrochloride
Form Tablet (Oral), Solution for Injection (IV)
Pharmacological class Antiarrhythmic Agent (Vaughan Williams Class III)
General purpose Stabilizing abnormal heart rhythms
Origin Synthetic (Benzofuran derivative)

What Type of Medicine is Amiorone?

Amiorone is a prescription-only medication whose active ingredient is Amiodarone Hydrochloride, broadly classified as a specialized Antiarrhythmic Agent. Its core function is to stabilize and regulate the electrical rhythm of the heart.

The drug is officially designated as a Vaughan Williams Class III antiarrhythmic, which indicates its primary mode of action is to delay the electrical recovery phase (repolarization) in the heart muscle cells. This classification makes it a cornerstone in managing a wide range of rhythm disorders. The compound is a synthetic benzofuran derivative that contains iodine, categorizing it as an iodinated compound.

Composition and Available Forms

The active substance, Amiodarone Hydrochloride, is the sole therapeutic component in this single-active-ingredient product. The medicine is manufactured in two key pharmaceutical preparations: an oral tablet for sustained use and a sterile solution for intravenous injection used in acute care settings.

The injectable form is designed as an aqueous micellar solution, typically including a solubilizer, to ensure effective administration directly into the bloodstream. This dual availability ensures that therapeutic effects can be accessed rapidly in an urgent clinical situation and maintained over the long term through the oral route. Amiodarone serves a significant role in critical care settings for the control of ventricular arrhythmias.

The Principle of Amiodarone’s Action

The main function of Amiodarone is to achieve effective electrical stabilization by directly influencing the heart's natural cycle. It operates by blocking specific potassium channels within the cardiac tissue, which extends the duration of the electrical recovery period between heartbeats. This action causes an increase in the refractory period—an extended time during which the heart cells cannot be prematurely re-excited—thereby dampening erratic electrical signals. By electrically stabilizing the pathways, the drug’s fundamental benefit is to help the heart maintain a coordinated, steady, and efficient rhythm.

Regulatory References

  1. World Health Organization (WHO)
  2. Amiodarone: MedlinePlus Drug Information

What side effects are possible with Amiorone?

Possible side effects and safety information

The official safety profile for Amiorone (Amiodarone Hydrochloride) is characterized by a spectrum of adverse effects that primarily involve several major organ systems, reflecting the drug’s ability to accumulate in the body. Regulatory documents classify these effects by frequency and system-organ class.

Key Adverse Reaction Classifications

Adverse reactions are formally grouped in regulatory labeling. Those classified as Very Common (occurring in 1 in 10 or more people) include corneal microdeposits (often reversible, causing visual halos) and gastrointestinal effects like nausea. Common effects (1 in 100 to less than 1 in 10) involve the endocrine system (hypothyroidism or hyperthyroidism), nervous system (peripheral neuropathy), and skin (photosensitivity). Uncommon effects include the onset or worsening of arrhythmia and cardiac conduction disturbances.

Serious Adverse Reactions and Organ Systems

The most clinically significant adverse reactions are classified as serious and may affect the:

  • Respiratory System: The risk of pulmonary toxicity, including interstitial pneumonitis and pulmonary fibrosis, is documented as potentially fatal.
  • Hepatic System: Severe, life-threatening hepatic injury, including acute liver failure and chronic cirrhosis, is officially listed.
  • Cardiac System: The potential for proarrhythmia—worsening of existing or development of new, serious ventricular arrhythmias—is a documented risk.

Safety Patterns and Constraints

Adverse effects may persist for several weeks to months following discontinuation due to the drug’s notably long half-life. Blue-gray skin discoloration is associated with long-term exposure. The official label establishes safety limitations, noting the drug should not be used in individuals with pre-existing conditions like sick sinus syndrome or high-degree AV block leading to syncope, unless a functioning pacemaker is present. Safety and efficacy in the pediatric population have not been established by adequate studies.

Overdose and Emergency Response

Overdose and when to seek help

Domain Official Regulatory Statement
Documented Manifestations Symptoms of an Amiorone overdose, based on official regulatory labeling, primarily involve the cardiovascular system and include profound slow heart rate (bradycardia), hypotension (low blood pressure), and potentially Atrioventricular (AV) block or shock. Other documented manifestations may include nausea, blurred vision, lightheadedness, and fainting.
Urgent Help Required Regulatory authorities explicitly require individuals to seek emergency medical treatment or call a doctor immediately if any signs of overdose are suspected. This is due to the potential for severe outcomes.

Official Overdose Statements

Overdose with Amiorone carries a serious risk of a fatal outcome due to its potential to cause or exacerbate life-threatening arrhythmias, including new ventricular fibrillation. Liver toxicity is also listed as a potential severe physiological effect.

The management protocol described in regulatory documents centers on aggressive symptomatic and supportive treatment. This may include administering intravenous fluids, vasopressors, or positive inotropic agents to stabilize circulation. Temporary cardiac pacing may be required to counteract severe bradycardia or heart block. Furthermore, the official prescribing information notes that Amiorone and its active metabolite are not removable by dialysis, imposing a key constraint on clinical intervention. Liver function must also be monitored regularly during overdose management.

Therapeutic Uses of Amiorone

What Amiodarone Treats: Main Uses and Benefits

Amiodarone is primarily reserved for managing conditions characterized by periods of heightened symptoms related to recurrent electrical instability in the heart. The medication is relevant across domains where additional symptomatic support is needed and is commonly used when other antiarrhythmic therapies have not been fully effective. It is used to help manage highly disruptive episodes of Recurrent Ventricular Fibrillation (VF) and unstable Ventricular Tachycardia (VT), as well as complex Supraventricular Tachyarrhythmias like Atrial Fibrillation (AF) and Atrial Flutter.

In clinical scenarios involving acute or unstable symptom patterns, the medication provides support that helps ease the overall symptom load during critical episodes. For long-term management, it provides supportive relief when symptoms interfere with routine activities, and contributes to easing the overall symptom load related to persistent electrical excitability. The medication assists with maintaining functional stability during symptomatic phases and supports patients during episodes of heightened discomfort related to rapid, irregular heartbeats.

Quick Fact: Use for Symptomatic Management

Property Description
Primary Use Used for managing severe and episodic rhythm disturbances
Target Symptoms Symptoms related to rapid and irregular heartbeat, electrical instability, palpitations
Key Benefit Supports functional stability and helps ease the overall symptom load
Severity Relevance Applied in severe, recurrent, or refractory rhythm disorders

Regulatory References

  1. DailyMed official labeling (NIH/NLM)

Eligibility and Restrictions for Use

Amiorone is an antiarrhythmic medication whose use is strictly reserved by regulatory bodies for documented, life-threatening recurrent ventricular arrhythmias that have not responded to other antiarrhythmic agents or when other agents are not tolerated.

Contraindications (Who Must Not Use Amiorone)

The medicine is formally contraindicated and must not be used by patients with:

  • Known hypersensitivity to amiorone, any of its components, or to iodine.
  • Cardiogenic shock.
  • Marked sinus bradycardia (slow heartbeat) or sick sinus syndrome.
  • Second- or third-degree AV block or other severe heart conduction disturbances, unless a functioning artificial pacemaker is present.
  • Evidence or a history of thyroid dysfunction.
  • Concomitant use with specific drugs that are known to induce a serious heart rhythm abnormality called Torsades de Pointes.

Eligibility Restrictions

  • Pregnancy and Lactation: Use during pregnancy is contraindicated except in exceptional circumstances due to the risk of fetal harm. It is also contraindicated for use while breastfeeding.
  • Pediatric Patients: The safety and effectiveness have not been established in the pediatric population.
  • Pre-existing Conditions: Caution is advised, and the drug is not generally recommended, in patients with pre-existing pulmonary disease or latent/manifest heart failure.

The final decision on eligibility is made by a specialist, who will weigh the drug’s use against the severity of the life-threatening heart condition.

What should I know about interactions with other medicines?

Amiorone (Amiodarone Hydrochloride) has a complex interaction profile documented across regulatory sources, defined primarily by its widespread effects on drug metabolism and cardiac electrophysiology.

Pharmacokinetic Interactions

Amiorone is officially noted as a potent inhibitor of multiple drug-metabolizing enzymes, including CYP2C9, CYP2D6, and CYP3A4. This inhibition results in an increase in the plasma concentration and exposure of co-administered medicines that are substrates for these enzymes, such as Warfarin, Phenytoin, and certain statins (like Simvastatin). Furthermore, Amiorone inhibits the efflux transporter P-glycoprotein (P-gp), which is documented to increase the exposure of P-gp substrates, notably Digoxin.

Pharmacodynamic and Contraindicated Interactions

Official labeling classifies co-administration with other medicines that prolong the QT interval (e.g., other Class I and Class III antiarrhythmics, specific antibiotics) as contraindicated, due to the additive pharmacodynamic risk of Torsade de Pointes. Caution is also advised regarding the combined use of Amiorone with negative chronotropes (e.g., beta-blockers) due to the risk of excessive bradycardia.

Food and Substance Interactions

Specific interactions with non-medicinal substances are documented. Grapefruit Juice is officially noted to increase Amiorone's plasma concentration by inhibiting CYP3A4. Conversely, the herbal product St. John's Wort is documented to reduce Amiorone serum levels due to enzyme induction. Oral Amiorone absorption is officially documented to be enhanced by food, requiring consistent daily administration relative to meals to maintain stable exposure.

Mechanism of Action

Broad-Spectrum Electrical Stabilizer

Amiodarone's primary action involves simultaneously blocking multiple voltage-gated ion channels—specifically potassium, sodium, and calcium—in the cardiac muscle cells. This multifaceted inhibition prolongs the cardiac action potential and the effective refractory period. This alters the electrophysiological environment, reducing myocardial excitability and inhibiting the re-entry of electrical impulses.

Autonomic and Hormonal Dampening

The drug also acts as an antagonist of beta-adrenergic receptors and interferes with the action of thyroid hormones on the heart due to structural similarity. This action reduces the influence of sympathetic and thyroid hormone-mediated signaling on the heart rate and excitability.

Conduction Delay and Vascular Effects

The combined effect of channel and receptor block slows the speed of electrical impulse transmission, particularly through the atrioventricular (AV) node. Physiologically, this results in a reduced heart rate and, particularly with intravenous administration, causes vasodilation, which lowers peripheral resistance and reduces mechanical strain on the myocardium.

Dosage and Administration Information

How to use Amiorone

Amiodarone is administered via two primary routes: oral tablets for chronic management and a sterile intravenous (IV) solution for the acute stabilization of electrical instability. The usage protocol is defined by a phased, titrating dose structure.

Oral Regimen and Timing

Oral administration begins with a high loading dose ranging from 800 to 1600 mg daily, typically lasting 1 to 3 weeks. This phase is followed by a reduction to an intermediate dose, before settling into a long-term maintenance dose, commonly 400 mg once per day. The tablets must be taken consistently with regard to meals to maintain stable absorption, as food significantly enhances drug uptake.

Intravenous Use and Transition

The IV form is typically utilized in the hospital setting and delivered as a continuous, multi-rate infusion over the first 24 hours, often totaling approximately 1000 mg. This includes an initial rapid load, followed by slower infusion rates.

Standard preparation includes dilution in D5W and administration in glass or non-PVC containers; for infusions exceeding one hour, the concentration should not exceed 2 mg/mL unless a central venous catheter is employed.

Once the acute phase is stabilized, patients are transitioned from the IV to the oral therapy, with the subsequent starting oral dose selected based on the duration of prior intravenous administration. The medicine’s safety and efficacy in pediatric populations have not been established.

Recent Clinical Evidence

Research Evidence Overview: Amiorone Studies

Evidence for Managing Life-Threatening Ventricular Rhythms

Amiorone was evaluated in research contexts exploring severe abnormal heart rhythms, specifically Ventricular Tachycardia (VT) and Ventricular Fibrillation (VF). The research base includes Randomized Controlled Trials (RCTs) and meta-analyses that compared Amiorone to a control (such as a placebo or other rhythm medicines). Researchers explored these issues in patients who had experienced these rhythms previously, including those with pre-existing conditions like Congestive Heart Failure or those who had recently experienced a heart attack (post-Myocardial Infarction).

Research examined comparative outcomes against non-drug devices (like the ICD) in high-risk patients, and findings were mixed regarding overall long-term survival measurements. Research explored measurements of heart rhythm patterns, but certainty remains low regarding whether the study findings showed a difference in total survival measurements compared to non-drug options in certain high-risk secondary prevention populations.

Evidence for Use in Acute Cardiac Arrest

The research was evaluated in emergency and pre-hospital settings where patients were experiencing a sudden acute episode of shock-refractory cardiac arrest. These Randomized Controlled Trials were conducted to examine temporary physiological imbalance and focused on two types of outcomes: the immediate endpoint of achieving a Return of Spontaneous Circulation (ROSC) and the definitive outcome of survival to hospital discharge.

Some studies reported measurements of survival to hospital admission that was observed in some studies when compared to a placebo or other antiarrhythmic agents. However, the findings were mixed across major research when measuring the ultimate outcome of survival to hospital discharge with a favorable neurological status.

What remains uncertain: Due to the mixed findings, there is a lack of consistent, conclusive evidence regarding whether study findings demonstrated a difference in the outcome of survival to hospital discharge with a favorable neurological outcome compared to other treatments.

Evidence for Supraventricular Tachyarrhythmias

Studies have consisted of various RCTs and systematic reviews that compared Amiorone to placebo and other medicines used for rhythm control for conditions characterized by fluctuating or episodic manifestations like Atrial Fibrillation (AF) and Atrial Flutter (AFl). These trials explored two main outcomes: the measured rates of conversion of the irregular rhythm and the subsequent maintenance of a steady heart rhythm over defined time intervals.

Research describes patterns observed where the measured rates of conversion to normal sinus rhythm and maintenance of heart rhythm were different in observed populations when compared to control groups. Long-term follow-up data for sustained heart rhythm patterns beyond one year is not fully established in some specific patient subgroups.

Key Studies & References

  1. Effectiveness of amiodarone for conversion of atrial fibrillation to sinus rhythm: a meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Amiorone (FAQ)


Q: How quickly does Amiorone typically start working?

According to official product information, the timeframe for the medicine to begin stabilizing heart rhythms can vary. For the oral tablet form, the effects are commonly observed after 1 to 3 weeks of continuous use, though the earliest onset is described as 2 to 3 days. The intravenous form, used in acute care, is noted to show electrical effects within hours.


Q: What happens if I forget to take Amiorone?

Official patient information describes the recommended approach for a missed dose: it may be taken when remembered. However, if it is almost time for the next scheduled dose, the instruction is to skip the missed dose and continue with the regular schedule. Doubling up on doses is generally not documented.


Q: How long can a person safely take Amiorone?

The required duration of treatment is determined by the patient's specific life-threatening condition. For certain chronic arrhythmias, regulatory information indicates a long-term maintenance treatment is often necessary. The drug has an extremely long half-life, meaning the medication's effects and potential adverse reactions may persist for several weeks to months after it is discontinued.


Q: What is the difference between Amiorone and other anti-arrhythmic drugs?

Amiorone is officially designated as a Vaughan Williams Class III antiarrhythmic agent. This classification means its primary function is to delay the electrical recovery phase (repolarization) in the heart muscle cells. It is described as having the ability to block multiple ion channels (potassium, sodium, and calcium) and also possess alpha- and beta-blocking properties, making its action multi-faceted compared to some other classes.


Q: Is it true that Amiorone can cause skin discoloration?

Yes, a blue-gray or slate-gray pigmentation of skin that has been exposed to the sun is a documented adverse reaction associated with long-term use. This discoloration is described in official contexts as reversible and typically resolves over several months after the medicine is discontinued.


Q: Is it normal to feel tired when starting Amiorone?

Fatigue (feeling tired) is listed among the possible side effects of Amiorone that have been reported in post-marketing or clinical studies. This symptom is often grouped within the category of effects on the central nervous system.


Q: Can Amiorone be used by people with kidney problems?

Regulatory documents indicate that existing renal impairment (kidney problems) does not have a marked effect on the drug's activity in the body (pharmacokinetics). The medicine is primarily processed and eliminated through the liver, with negligible removal by the kidneys.


Q: Does Amiorone cause weight gain or loss?

Weight changes are listed in official patient information as a potential symptom that may occur. This includes both weight loss and weight gain, which are often associated with the medication’s documented effect on thyroid function.


Q: Is there a generic version of Amiorone available?

Yes, the active ingredient, Amiodarone Hydrochloride, is available in an FDA-approved generic oral tablet form. The sterile solution for injection is noted as not having an FDA-approved generic formulation currently available.


Q: Does Amiorone cause hair loss?

Thinning hair is listed in regulatory-based patient information as a possible symptom that may occur. This effect is sometimes seen in connection with documented changes in thyroid function.


Q: Do I need to change my diet while taking Amiorone?

Official labeling only documents specific interactions with a few substances, namely Grapefruit juice (increases drug levels) and the herbal product St. John's Wort (reduces drug levels). No other general dietary restrictions are mandated in regulatory documents.


Q: Is Amiorone taken daily?

The initial phase of therapy, which includes a high dose, is taken daily for a defined period. Following this, the long-term maintenance dose is also typically prescribed to be taken once per day.


Q: Does Amiorone interact with alcohol?

Some official patient information states that limiting the intake of alcohol is associated with taking the medicine. This is due to the documented potential for the drug to cause liver problems.


Q: Can Amiorone be taken with dairy products?

Official labeling does not mention specific interactions with dairy products. The medicine is required to be taken consistently with food (meals) to help maintain stable drug levels in the body, as food is known to enhance its uptake.


Q: Is Amiorone the same as amiodarone?

Yes, the active ingredient is officially identified as Amiodarone Hydrochloride, which is the internationally recognized generic name. Amiorone is a product name containing this active ingredient.


Q: Can Amiorone affect fertility?

The official prescribing information addresses the potential for Impairment of Fertility as part of its comprehensive safety documentation. This information is based on findings from non-clinical (animal) studies.


Q: Are there any restrictions on driving while taking Amiorone?

A possible side effect is the development of corneal microdeposits in the eye, which can cause dazzling, particularly when looking at bright lights at night. Official patient information describes that driving at night is generally not recommended if this visual effect occurs.

How should Amiorone be stored and disposed of?

Amiodarone Storage and Disposal

Amiodarone tablets must be stored at Controlled Room Temperature, typically between 20 C and 25 C (68 F and 77 F). The medication requires protection from excessive heat and moisture and must not be refrigerated. Tablets should remain in the original container and be kept tightly closed.

Unopened vials of the injectable solution are also stored at room temperature and must be protected from light and freezing. The final diluted IV solution has specific stability limits: 24 hours at room temperature or 48 hours if refrigerated.

All forms of Amiodarone must be stored out of the sight and reach of children. Unused or expired medication should never be disposed of in household trash or poured down a drain, but must be returned to a drug take-back program or disposed of according to local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Amiorone found in:

A-Z Index: